MA33661B1 - Polypeptides pour liaison au "récepteur des produits finaux de glycation avancée" et compositions et procédés mettant en oeuvre ceux-ci - Google Patents
Polypeptides pour liaison au "récepteur des produits finaux de glycation avancée" et compositions et procédés mettant en oeuvre ceux-ciInfo
- Publication number
- MA33661B1 MA33661B1 MA34756A MA34756A MA33661B1 MA 33661 B1 MA33661 B1 MA 33661B1 MA 34756 A MA34756 A MA 34756A MA 34756 A MA34756 A MA 34756A MA 33661 B1 MA33661 B1 MA 33661B1
- Authority
- MA
- Morocco
- Prior art keywords
- polypeptide
- rabies
- advanced glycation
- glycation end
- polypeptides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Rheumatology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
Abstract
La présente invention concerne un polypeptide ou complexe polypeptidique comprenant au moins les deux séquences d'acides aminés conçues pour permettre une liaison spécifique au « récepteur de produits terminaux de glycation avancée » (rage), un ou plusieurs acides nucléiques codant pour le polypeptide ou complexe polypeptidique, une cellule produisant un anticorps dirigé contre rage, une composition pharmaceutique comprenant au moins un polypeptide ou acide nucléique tel que défini ci-dessus, facultativement pour traiter une maladie ou un trouble lié à rage. L'invention concerne également un procédé de diagnostic d'une maladie ou d'un trouble lié à rage.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09290778A EP2308896A1 (fr) | 2009-10-09 | 2009-10-09 | Polypeptides pour liaison au récepteur des produits finaux de la glycosylation avancée et compositions et procédés les impliquant |
EP09290845A EP2319871A1 (fr) | 2009-11-05 | 2009-11-05 | Polypeptides pour liaison au récepteur des produits finaux de la glycosylation avancée et compositions et procédés les impliquant |
PCT/EP2010/065124 WO2011042548A1 (fr) | 2009-10-09 | 2010-10-08 | Polypeptides de liaison au « récepteur de produits terminaux de glycation avancée » ainsi que compositions et procédés les mettant en jeu |
Publications (1)
Publication Number | Publication Date |
---|---|
MA33661B1 true MA33661B1 (fr) | 2012-10-01 |
Family
ID=43448431
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA34756A MA33661B1 (fr) | 2009-10-09 | 2012-04-04 | Polypeptides pour liaison au "récepteur des produits finaux de glycation avancée" et compositions et procédés mettant en oeuvre ceux-ci |
Country Status (19)
Country | Link |
---|---|
US (1) | US20120282637A1 (fr) |
EP (1) | EP2486058A1 (fr) |
JP (1) | JP2013507115A (fr) |
KR (1) | KR20120089863A (fr) |
CN (1) | CN102686611A (fr) |
AU (1) | AU2010305374A1 (fr) |
BR (1) | BR112012007821A2 (fr) |
CA (1) | CA2777237A1 (fr) |
CL (1) | CL2012000886A1 (fr) |
CR (1) | CR20120139A (fr) |
EC (1) | ECSP12011787A (fr) |
IL (1) | IL218968A0 (fr) |
MA (1) | MA33661B1 (fr) |
MX (1) | MX2012004090A (fr) |
PE (1) | PE20121689A1 (fr) |
RU (1) | RU2558301C2 (fr) |
TN (1) | TN2012000138A1 (fr) |
WO (1) | WO2011042548A1 (fr) |
ZA (1) | ZA201202099B (fr) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA112434C2 (uk) | 2011-05-27 | 2016-09-12 | Ґлаксо Ґруп Лімітед | Антигензв'язувальний білок, який специфічно зв'язується з всма |
GB201200563D0 (en) * | 2012-01-13 | 2012-02-29 | Imp Innovations Ltd | Binding molecule |
WO2014167826A1 (fr) * | 2013-04-08 | 2014-10-16 | 株式会社免疫生物研究所 | ANTICORPS RECONNAISSANT SPÉCIFIQUEMENT LA SURFACE DE CLIVAGE DU FRAGMENT C-TERMINAL APRÈS CLIVAGE DU PRÉCURSEUR DE LA PROTÉINE AMYLOÏDE PAR L'α-SÉCRÉTASE ET SON UTILISATION |
WO2014197460A1 (fr) * | 2013-06-04 | 2014-12-11 | The Trustees Of The University Of Pennsylvania | Procédés de diagnostic et de traitement de la bicuspidie valvulaire aortique et/ou d'aortopathies |
MY176282A (en) | 2013-08-30 | 2020-07-27 | Immunogen Inc | Antibodies and assays for detection of folate receptor 1 |
EP3077823B1 (fr) | 2013-12-05 | 2019-09-04 | The Broad Institute, Inc. | Compositions et méthodes pour identifier et traiter la cachexie ou la pré-cachexie |
WO2016061532A1 (fr) * | 2014-10-16 | 2016-04-21 | The Broad Institute Inc. | Compositions et méthodes pour identifier et traiter la cachexie ou la pré-cachexie |
JP6679096B2 (ja) * | 2014-10-21 | 2020-04-15 | 学校法人 久留米大学 | Rageアプタマーおよびその用途 |
US10626176B2 (en) | 2014-10-31 | 2020-04-21 | Jounce Therapeutics, Inc. | Methods of treating conditions with antibodies that bind B7-H4 |
AU2016262100B2 (en) * | 2015-05-12 | 2021-10-14 | Syntimmune, Inc. | Humanized affinity matured anti-FcRn antibodies |
WO2016187354A1 (fr) | 2015-05-18 | 2016-11-24 | Agensys, Inc. | Anticorps se liant à des protéines axl |
EP3297663A4 (fr) | 2015-05-18 | 2018-12-19 | Agensys, Inc. | Anticorps qui se lient aux protéines axl |
WO2016201319A1 (fr) * | 2015-06-10 | 2016-12-15 | The Broad Institute Inc. | Anticorps, composés et écrans d'identification et de traitement de cachexie ou pré-cachexie |
US20180355033A1 (en) | 2015-06-10 | 2018-12-13 | Dana-Farber Cancer Institute, Inc. | Antibodies, compounds and screens for identifying and treating cachexia or pre-cachexia |
JP6578595B2 (ja) * | 2015-08-28 | 2019-09-25 | 国立研究開発法人科学技術振興機構 | 抗アセチル化ヒストンh4抗体 |
RU2719158C2 (ru) * | 2015-09-08 | 2020-04-17 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Антитело к epha4 |
CA2994888A1 (fr) | 2015-09-17 | 2017-03-23 | Immunogen, Inc. | Combinaisons therapeutiques comprenant des immunoconjugues anti-folr1 |
WO2017106196A1 (fr) | 2015-12-14 | 2017-06-22 | The Broad Institute, Inc. | Compositions et procédés de traitement des dysfonctionnements cardiaques |
CN108570106B (zh) * | 2017-03-10 | 2021-07-16 | 北京天广实生物技术股份有限公司 | 抗埃博拉病毒单克隆抗体、其制备方法及用途 |
AU2018312222A1 (en) | 2017-08-02 | 2020-02-27 | Phanes Therapeutics, Inc. | Anti-CD47 antibodies and uses thereof |
CN113226367A (zh) | 2018-04-06 | 2021-08-06 | Atyr 医药公司 | 包括抗nrp2抗体的组合物和方法 |
US11345744B2 (en) | 2019-05-07 | 2022-05-31 | William R Church | Antibody specific to Staphylococcus aureus, therapeutic method and detection method using same |
AU2020308053A1 (en) * | 2019-06-26 | 2022-01-20 | Glaxosmithkline Intellectual Property Development Limited | IL1RAP binding proteins |
CA3156803A1 (fr) * | 2019-10-03 | 2021-04-08 | Atyr Pharma, Inc. | Compositions et methodes comprenant des anticorps anti-nrp2 |
WO2022019924A1 (fr) * | 2020-07-23 | 2022-01-27 | Church William R | Anticorps spécifique de staphylococcus aureus, méthode thérapeutique et méthode de détection de celui-ci |
CN113956363B (zh) * | 2021-10-13 | 2023-03-31 | 宜明昂科生物医药技术(上海)股份有限公司 | 靶向cd47和cd24的重组融合蛋白及其制备和用途 |
CN116554311B (zh) * | 2023-05-04 | 2023-11-21 | 中国人民解放军军事科学院军事医学研究院 | 抗CD2v-N的特异性抗体及其应用 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
ATE328890T1 (de) | 1994-07-15 | 2006-06-15 | Univ Iowa Res Found | Immunomodulatorische oligonukleotide |
US5864018A (en) * | 1996-04-16 | 1999-01-26 | Schering Aktiengesellschaft | Antibodies to advanced glycosylation end-product receptor polypeptides and uses therefor |
ZA988461B (en) * | 1997-09-18 | 1999-03-30 | Idec Pharma Corp | Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis |
AT409085B (de) | 2000-01-28 | 2002-05-27 | Cistem Biotechnologies Gmbh | Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen |
AT410173B (de) | 2000-06-08 | 2003-02-25 | Cistem Biotechnologies Gmbh | Antigene zusammensetzung |
AU8181201A (en) | 2000-06-08 | 2001-12-17 | Cistem Biotechnologies Gmbh | Immunostimulatory oligodeoxynucleotides |
CA2418854A1 (fr) | 2000-08-17 | 2002-02-21 | Jorg Fritz | Vaccin comprenant au moins un antigene et un peptide antimicrobien a base de cathelicidine ou un derive de ce peptide |
AT410635B (de) | 2000-10-18 | 2003-06-25 | Cistem Biotechnologies Gmbh | Vakzin-zusammensetzung |
CA2447793A1 (fr) | 2001-05-21 | 2002-11-28 | Intercell Ag | Molecules oligodesoxynucleiques immunostimulatrices |
US7425328B2 (en) * | 2003-04-22 | 2008-09-16 | Purdue Pharma L.P. | Tissue factor antibodies and uses thereof |
US20080008719A1 (en) * | 2004-07-10 | 2008-01-10 | Bowdish Katherine S | Methods and compositions for the treatment of prostate cancer |
US20090155799A1 (en) * | 2006-03-02 | 2009-06-18 | Yusuke Nakamura | Methods for diagnosing pancreatic cancer using reg4 protein |
CN101448857A (zh) * | 2006-03-21 | 2009-06-03 | 惠氏公司 | 预防和治疗淀粉样蛋白生成疾病的方法 |
BRPI0708970A2 (pt) * | 2006-03-21 | 2011-06-21 | Wyeth Corp | método para o tratamento de um sujeito com uma doença ou transtorno caracterizado por depósito amilóide de a-beta; método de inibição ou redução da acumulação de depósito amilóide de a-beta em um sujeito; método de inibição ou redução da neurodegeneração em um sujeito; e método de inibição ou redução do declìnio cognitivo, ou de melhora da cognição, em um sujeito |
WO2007147901A1 (fr) * | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production d'anticorps bispécifiques |
CN100586960C (zh) * | 2006-06-23 | 2010-02-03 | 陈志南 | HAb18GC2单抗和其轻、重链可变区基因及应用 |
WO2008137552A2 (fr) * | 2007-05-02 | 2008-11-13 | Medimmune, Llc | Anticorps anti-rage et procédés d'utilisation de ceux-ci |
AU2009245354C1 (en) * | 2008-05-09 | 2016-05-19 | AbbVie Deutschland GmbH & Co. KG | Antibodies to receptor of advanced glycation end products (RAGE) and uses thereof |
-
2010
- 2010-10-08 AU AU2010305374A patent/AU2010305374A1/en not_active Abandoned
- 2010-10-08 KR KR1020127011908A patent/KR20120089863A/ko not_active Application Discontinuation
- 2010-10-08 BR BR112012007821A patent/BR112012007821A2/pt not_active IP Right Cessation
- 2010-10-08 MX MX2012004090A patent/MX2012004090A/es not_active Application Discontinuation
- 2010-10-08 WO PCT/EP2010/065124 patent/WO2011042548A1/fr active Application Filing
- 2010-10-08 PE PE2012000444A patent/PE20121689A1/es not_active Application Discontinuation
- 2010-10-08 US US13/500,400 patent/US20120282637A1/en not_active Abandoned
- 2010-10-08 RU RU2012118598/10A patent/RU2558301C2/ru not_active IP Right Cessation
- 2010-10-08 EP EP10771381A patent/EP2486058A1/fr not_active Withdrawn
- 2010-10-08 CN CN201080045826XA patent/CN102686611A/zh active Pending
- 2010-10-08 CA CA2777237A patent/CA2777237A1/fr not_active Abandoned
- 2010-10-08 JP JP2012532622A patent/JP2013507115A/ja active Pending
-
2012
- 2012-03-22 ZA ZA2012/02099A patent/ZA201202099B/en unknown
- 2012-03-22 CR CR20120139A patent/CR20120139A/es unknown
- 2012-03-27 TN TNP2012000138A patent/TN2012000138A1/en unknown
- 2012-04-01 IL IL218968A patent/IL218968A0/en unknown
- 2012-04-04 MA MA34756A patent/MA33661B1/fr unknown
- 2012-04-05 CL CL2012000886A patent/CL2012000886A1/es unknown
- 2012-04-05 EC ECSP12011787 patent/ECSP12011787A/es unknown
Also Published As
Publication number | Publication date |
---|---|
RU2558301C2 (ru) | 2015-07-27 |
AU2010305374A1 (en) | 2012-05-03 |
RU2012118598A (ru) | 2013-11-20 |
ECSP12011787A (es) | 2012-10-30 |
IL218968A0 (en) | 2012-07-31 |
WO2011042548A1 (fr) | 2011-04-14 |
EP2486058A1 (fr) | 2012-08-15 |
CN102686611A (zh) | 2012-09-19 |
US20120282637A1 (en) | 2012-11-08 |
ZA201202099B (en) | 2012-11-28 |
CR20120139A (es) | 2012-07-13 |
BR112012007821A2 (pt) | 2017-05-30 |
CA2777237A1 (fr) | 2011-04-14 |
TN2012000138A1 (en) | 2013-09-19 |
JP2013507115A (ja) | 2013-03-04 |
MX2012004090A (es) | 2012-04-20 |
CL2012000886A1 (es) | 2012-12-14 |
KR20120089863A (ko) | 2012-08-14 |
PE20121689A1 (es) | 2012-12-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA33661B1 (fr) | Polypeptides pour liaison au "récepteur des produits finaux de glycation avancée" et compositions et procédés mettant en oeuvre ceux-ci | |
Chung et al. | Effects of antibody disulfide bond reduction on purification process performance and final drug substance stability | |
MA34475B1 (fr) | Peptide ou complexe de peptide se liant a l'integrine a2 et procedes et utilisation mettant en oeuvre ceux-ci | |
WO2009017679A3 (fr) | Anticorps spécifiques de igf-1r utiles dans la détection et le diagnostic de troubles de prolifération cellulaire | |
CN1596371A (zh) | 新的自组装分子 | |
GEP20146112B (en) | Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and usage thereof | |
IL210485A (en) | An isolated antibody or its functional protein, a process for making it, a pharmaceutical preparation containing it, and an isolated amino acid encoding an antibody or a functional protein | |
WO2007109747A3 (fr) | Procédés et compositions destinés à un antagonisme de rage | |
MX2012011405A (es) | Anticuerpo biespecifico psmaxcd3 de simple cadena especifico de especies cruzadas. | |
WO2008054543A3 (fr) | Oligonucléotides pour l'assemblage mutiplexé d'acides nucléiques | |
WO2007042261A3 (fr) | Compositions comportant des anticorps specifiques d'especes croisees et leurs utilisations | |
UA102061C2 (ru) | Агонистическое антитело к notch3 и его применение для лечения notch3- ассоциированных заболеваний | |
WO2007010080A3 (fr) | Nouveaux dendrimeres carbosilanes, leur preparation et leur utilisation | |
MA34053B1 (fr) | Polypeptides agonistes de liaison à dr5 | |
AU2020247918B2 (en) | Modified cleavases, uses thereof and related kits | |
WO2008135446A3 (fr) | Antigènes de la klebsiella | |
CN103201288A (zh) | 通过混合模式层析捕捉抗体的优化方法 | |
EP3162895A1 (fr) | Protéine de liaison au récepteur fc améliorée, procédé de production de ladite protéine, anticorps adsorbant utilisant ladite protéine, et procédés de séparation d'anticorps au moyen dudit adsorbant | |
WO2010092176A3 (fr) | Antigènes haemophilus influenzae non typables | |
WO2011053065A3 (fr) | Dérivé de poly(éthylèneglycol) avec catéchol et conjugués protéiques ou peptidiques, et leur procédé de préparation | |
WO2004094476A3 (fr) | Compositions et methodes se rapportant a stop-1 | |
WO2009138494A3 (fr) | Séquences d'acides aminés dirigées contre des récepteurs du type toll et polypeptides comprenant celles-ci pour le traitement de maladies apparentées aux récepteurs du type toll | |
WO2009115508A3 (fr) | Peptides luttant contre s. pneumoniae et compositions, méthodes et utilisations associées | |
AU2020261039A1 (en) | Anti-CD38 antibodies and formulations | |
WO2008035222A3 (fr) | Synthèse d'acides aminés à structure glucidique et procédés d'utilisation correspondants |